keyword
MENU ▼
Read by QxMD icon Read
search

HFREF

keyword
https://www.readbyqxmd.com/read/28097518/beneficial-effects-of-ozone-therapy-on-oxidative-stress-cardiac-functions-and-clinical-findings-in-patients-with-heart-failure-reduced-ejection-fraction
#1
Mutlu Buyuklu, Fatih Mehmet Kandemir, Turan Set, Eftal Murat Bakırcı, Husnu Degirmenci, Hikmet Hamur, Ergun Topal, Sefa Kucukler, Kultigin Turkmen
The aim of study was to determine the effects of ozone therapy on the oxidative stress, cardiac functions and clinical findings in patients with heart failure reduced ejection fraction (HFrEF). A total of 40 patients with New York Heart Association 2 and 3 HF with left ventricular ejection fraction (LVEF) <35%, and 40 subjects without HF as control group were included in the study. Patients with HFrEF were given additional ozone therapy of major and minor administrations along with conventional HF treatment for 5 weeks...
January 17, 2017: Cardiovascular Toxicology
https://www.readbyqxmd.com/read/28094466/effects-of-beta-blockers-on-all-cause-mortality-in-patients-with-type-2-diabetes-and-coronary-heart-disease
#2
Tetsuro Tsujimoto, Takehiro Sugiyama, Hiroshi Kajio
AIMS: Although beta-blockers can prolong survival in patients with myocardial infarction (MI) and heart failure with reduced left ventricular ejection fraction (HFrEF), use of beta-blockers in patients with diabetes may cause hypoglycaemia and weight gain, which are associated with an increased risk of death and cardiovascular events. METHODS: Using the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial data, we performed Cox proportional hazards analysis to assess the effects of beta-blockers on all-cause mortality in 2,244 patients with type 2 diabetes who had stable coronary heart disease (CHD) with and without a prior history of MI/HFrEF...
January 17, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28090229/the-impact-exerted-on-clinical-outcomes-of-patients-with-chronic-heart-failure-by-aldosterone-receptor-antagonists-a-meta-analysis-of-randomized-controlled-trials
#3
Renato De Vecchis, Claudio Cantatrione, Damiana Mazzei, Augusto Barone, Nicola Maurea
BACKGROUND: Aldosterone receptor antagonists (ARAs) have been associated with improved clinical outcomes in patients with heart failure with reduced left ventricular ejection fraction (HFREF), but not in those with heart failure with preserved left ventricular ejection fraction (HFpEF). With the aim to study this topic more deeply, we carried out a meta-analysis of selective and non-selective ARAs in HFREF and HFpEF. METHODS: We searched PubMed and Scopus databases...
February 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28089316/decreased-mortality-with-beta-blockers-in%C3%A2-patients-with-heart-failure-and-coexisting-atrial-fibrillation-an-af-chf-substudy
#4
Julia Cadrin-Tourigny, Azadeh Shohoudi, Denis Roy, Mario Talajic, Rafik Tadros, Blandine Mondésert, Katia Dyrda, Léna Rivard, Jason G Andrade, Laurent Macle, Peter G Guerra, Bernard Thibault, Marc Dubuc, Paul Khairy
OBJECTIVES: The impact of beta-blockers on mortality and hospitalizations was assessed in the largest randomized trial of patients with both atrial fibrillation (AF) and heart failure with a reduced ejection fraction (HFrEF): the Atrial Fibrillation-Congestive Heart Failure trial. BACKGROUND: Although beta-blockers are the cornerstone of therapy for HFrEF, a recent patient-level meta-analysis cast doubt on their efficacy in patients with coexisting AF. METHODS: From a total of 1,376 subjects randomized in the AF-CHF trial, those without beta-blockers at baseline were propensity matched to a maximum of 2 exposed patients...
January 4, 2017: JACC. Heart Failure
https://www.readbyqxmd.com/read/28087180/a-comparison-of-hfref-vs-hfpef-s-clinical-workload-and-cost-in-the-first-year-following-hospitalization-and-enrollment-in-a-disease-management-program
#5
T M Murphy, D F Waterhouse, S James, C Casey, E Fitzgerald, E O'Connell, C Watson, J Gallagher, M Ledwidge, K McDonald
BACKGROUND: Admission with heart failure (HF) is a milestone in the progression of the disease, often resulting in higher intensity medical care and ensuing readmissions. Whilst there is evidence supporting enrolling patients in a heart failure disease management program (HF-DMP), not all reported HF-DMPs have systematically enrolled patients with HF with preserved ejection fraction (HFpEF) and there is a scarcity of literature differentiating costs based on HF-phenotype. METHODS: 1292 consenting, consecutive patients admitted with a primary diagnosis of HF were enrolled in a hospital based HF-DMP and categorized as HFpEF (EF≥45%) or HFrEF (EF<45%)...
December 23, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/28062623/a-novel-lipid-biomarker-panel-for-the-detection-of-heart-failure-with-reduced-ejection-fraction
#6
Matthias Mueller-Hennessen, Hans-Dirk Düngen, Matthias Lutz, Tobias Daniel Trippel, Michael Kreuter, Johanna Sigl, Oliver J Müller, Elvis Tahirovic, Henning Witt, Philipp Ternes, Susan Carvalho, Erik Peter, Dietrich Rein, Philipp Schatz, Felix Herth, Evangelos Giannitsis, Tanja Weis, Norbert Frey, Hugo A Katus
OBJECTIVES: In this study we aimed to identify novel metabolomic biomarkers suitable for improved diagnosis of heart failure with reduced ejection fraction (HFrEF). METHODS: We prospectively recruited 887 individuals consisting of HFrEF patients with either ischemic (ICMP, n = 257) or nonischemic cardiomyopathy (NICMP, n = 269), healthy controls (n = 327), and patients with pulmonary diseases (n = 34). A single-center identification (n = 238) was followed by a multicenter confirmation study (n = 649)...
January 2017: Clinical Chemistry
https://www.readbyqxmd.com/read/28052978/the-diabetic-hfpef-phenotype-is-it-real-and-is-it-worth-targeting-therapeutically
#7
Brian R Lindman
For investigators, physicians, and patients, the inability to identify therapies to improve clinical outcomes, particularly mortality, in patients with heart failure with preserved ejection fraction (HFpEF) has been particularly vexing and stands in stark contrast to the progress made in the treatment of patients with heart failure with reduced ejection fraction (HFrEF). This has prompted a return to the proverbial drawing board, forcing a reconsideration of long-held assumptions and paradigms. Despite different underlying etiologies, patients with HFrEF are generally responsive to several classes of medications that target the neurohormonal axis...
January 4, 2017: Circulation
https://www.readbyqxmd.com/read/28043438/surgical-experience-and-long-term-results-of-baroreflex-activation-therapy-for-heart-failure-with-reduced-ejection-fraction
#8
Fred A Weaver, William T Abraham, William C Little, Christian Butter, Anique Ducharme, Marcel Halbach, Didier Klug, Eric G Lovett, Navid Madershahian, Jochen Müller-Ehmsen, Jill E Schafer, Michele Senni, Vijay Swarup, Rolf Wachter, Michael R Zile
The purpose of this publication is to describe the intraoperative experience along with long-term safety and efficacy of the second-generation baroreflex activation therapy (BAT) system in patients with heart failure (HF) and reduced ejection fraction HF (HFrEF). In a randomized trial of New York Heart Association Class III HFrEF, 140 patients were assigned 1:1 to receive BAT plus medical therapy or medical therapy alone. Procedural information along with safety and efficacy data were collected and analyzed over 12 months...
July 2016: Seminars in Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28034849/comparison-of-neuropsychological-patterns-in-nigerians-with-different-heart-failure-phenotypes
#9
Philip B Adebayo, Adeseye A Akintunde, Anthonia J Adebayo, Stephen O Asaolu, Morenike Audu, Olugbenga E Ayodele
OBJECTIVE: The aim of this study was to determine the influence of left ventricular dysfunction type on the pattern of neuropsychological dysfunctions among heart failure (HF) subjects. METHOD: A sub-analysis of the data of subjects recruited in a cross-sectional survey of cognitive dysfunction among Nigerians with HF was performed. Cognitive performance on the Community Screening Interview for Dementia (CSI'D), Word List Learning Delayed Recall (WLLDR), Boston Naming Test (BNT), and Modified Token Test (MTT) were compared between heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF)...
December 28, 2016: Archives of Clinical Neuropsychology: the Official Journal of the National Academy of Neuropsychologists
https://www.readbyqxmd.com/read/28031211/model-based-cost-effectiveness-analysis-of-b-type-natriuretic-peptide-guided-care-in-patients-with-heart-failure
#10
Syed Mohiuddin, Barnaby Reeves, Maria Pufulete, Rachel Maishman, Mark Dayer, John Macleod, Theresa McDonagh, Sarah Purdy, Chris Rogers, William Hollingworth
OBJECTIVE: Monitoring B-type natriuretic peptide (BNP) to guide pharmacotherapy might improve survival in patients with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). However, the cost-effectiveness of BNP-guided care is uncertain and guidelines do not uniformly recommend it. We assessed the cost-effectiveness of BNP-guided care in patient subgroups defined by age and ejection fraction. METHODS: We used a Markov model with a 3-month cycle length to estimate the lifetime health service costs, quality-adjusted life years (QALYs) and incremental net monetary benefits (iNMBs) of BNP-guided versus clinically guided care in 3 patient subgroups: (1) HFrEF patients <75 years; (2) HFpEF patients <75 years; and (3) HFrEF patients ≥75 years...
December 28, 2016: BMJ Open
https://www.readbyqxmd.com/read/28030609/impact-of-exhaled-breath-acetone-in-the-prognosis-of-patients-with-heart-failure-with-reduced-ejection-fraction-hfref-one-year-of-clinical-follow-up
#11
Fabiana G Marcondes-Braga, Guilherme L Batista, Ivano G R Gutz, Paulo H N Saldiva, Sandrigo Mangini, Victor S Issa, Silvia M Ayub-Ferreira, Edimar A Bocchi, Alexandre Costa Pereira, Fernando Bacal
BACKGROUND: The identification of new biomarkers of heart failure (HF) could help in its treatment. Previously, our group studied 89 patients with HF and showed that exhaled breath acetone (EBA) is a new noninvasive biomarker of HF diagnosis. However, there is no data about the relevance of EBA as a biomarker of prognosis. OBJECTIVES: To evaluate whether EBA could give prognostic information in patients with heart failure with reduced ejection fraction (HFrEF). METHODS: After breath collection and analysis by gas chromatography-mass spectrometry and by spectrophotometry, the 89 patients referred before were followed by one year...
2016: PloS One
https://www.readbyqxmd.com/read/28029411/atrial-fibrillation-and-heart-failure-factors-influencing-the-choice-of-oral-anticoagulant
#12
REVIEW
Louise A E Brown, Christopher J Boos
Atrial fibrillation (AF) and heart failure (HF) frequently coexist. AF is identified in approximately one third of patients with HF and is linked to increased morbidity and mortality than from either condition alone. AF is relatively more common in HF with preserved ejection fraction (HFpEF) than with reduced ejection fraction (HFrEF). Nevertheless, the risk of stroke and systemic embolism (SSE) is significantly increased with both HF types and the absolute risk is heavily influenced by the presence and severity of associated additional stroke risk factors...
September 30, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/28025460/riser-pattern-is-a-novel-predictor-of-adverse-events-in-heart-failure-patients-with-preserved-ejection-fraction
#13
Takahiro Komori, Kazuo Eguchi, Toshinobu Saito, Satoshi Hoshide, Kazuomi Kario
BACKGROUND: The cardiovascular prognosis of heart failure with preserved ejection fraction (HFpEF) has been shown to be similar to that of heart failure with reduced ejection fraction (HFrEF). It is unknown which factors predict cardiovascular outcome in HFpEF. We tested the hypothesis that the abnormal pattern of circadian blood pressure (BP) rhythm known as the riser BP pattern is associated with adverse outcomes in HFpEF.Methods and Results:We performed a prospective, observational cohort study of hospitalized HF patients who underwent ambulatory BP monitoring (ABPM)...
December 23, 2016: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/28024961/efficacy-and-safety-of-sacubitril-valsartan-lcz696-in-japanese-patients-with-chronic-heart-failure-and-reduced-ejection-fraction-rationale-for-and-design-of-the-randomized-double-blind-parallel-hf-study
#14
Hiroyuki Tsutsui, Shinichi Momomura, Yoshihiko Saito, Hiroshi Ito, Kazuhiro Yamamoto, Tomomi Ohishi, Naoko Okino, Weinong Guo
BACKGROUND: The prognosis of heart failure patients with reduced ejection fraction (HFrEF) in Japan remains poor, although there is growing evidence for increasing use of evidence-based pharmacotherapies in Japanese real-world HF registries. Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). The prospectively designed phase III PARALLEL-HF (Prospective comparison of ARNI with ACE inhibitor to determine the noveL beneficiaL trEatment vaLue in Japanese Heart Failure patients) study aims to assess the clinical efficacy and safety of LCZ696 in Japanese HFrEF patients, and show similar improvements in clinical outcomes as the PARADIGM-HF study enabling the registration of LCZ696 in Japan...
December 23, 2016: Journal of Cardiology
https://www.readbyqxmd.com/read/28017395/left-atrial-function-dynamics-during%C3%A2-exercise-in-heart-failure-pathophysiological-implications-on-the-right-heart-and-exercise-ventilation-inefficiency
#15
Tadafumi Sugimoto, Francesco Bandera, Greta Generati, Eleonora Alfonzetti, Claudio Bussadori, Marco Guazzi
OBJECTIVES: The hypothesis of this study was that left atrial (LA) dynamic impairment during exercise may trigger right ventricular (RV)-to-pulmonary circulation (PC) uncoupling and ventilation inefficiency. BACKGROUND: LA function plays a key role in the hemodynamics of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Extensive investigation of LA dynamics, however, has been performed exclusively at rest...
December 12, 2016: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28011188/mid-range-ejection-fraction-does-not-permit-risk-stratification-among-patients-hospitalized-for-heart-failure
#16
Inés Gómez-Otero, Andreu Ferrero-Gregori, Alfonso Varela Román, José Seijas Amigo, Domingo A Pascual-Figal, Juan Delgado Jiménez, Jesús Álvarez-García, Francisco Fernández-Avilés, Fernando Worner Diz, Luis Alonso-Pulpón, Juan Cinca, José Ramón Gónzalez-Juanatey
INTRODUCTION AND OBJECTIVES: European Society of Cardiology heart failure guidelines include a new patient category with mid-range (40%-49%) left ventricular ejection fraction (HFmrEF). HFmrEF patient characteristics and prognosis are poorly defined. The aim of this study was to analyze the HFmrEF category in a cohort of hospitalized heart failure patients (REDINSCOR II Registry). METHODS: A prospective observational study was conducted with 1420 patients classified according to ejection fraction as follows: HFrEF, < 40%; HFmrEF, 40%-49%; and HFpEF, ≥ 50%...
December 20, 2016: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28004291/sacubitril-valsartan-lcz696-in-heart-failure
#17
Yasser Khder, Victor Shi, John J V McMurray, Martin P Lefkowitz
It has been known since the 1990s that long-term morbidity and mortality is improved in patients with heart failure with reduced ejection fraction (HFrEF) by treatments that target the renin-angiotensin-aldosterone system (RAAS). It has also long been thought that enhancement of the activity of natriuretic peptides (NPs) could potentially benefit patients with HFrEF, but multiple attempts to realize this benefit had failed over the years - until 2014, when a large, phase III, randomized, controlled clinical trial (PARADIGM-HF) was completed comparing sacubitril/valsartan with enalapril, a well-established treatment for HFrEF...
December 22, 2016: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/27999929/acute-heart-failure-with-mid-range-left-ventricular-ejection-fraction-clinical-profile-in-hospital-management-and-short-term-outcome
#18
Dimitrios Farmakis, Panagiotis Simitsis, Vasiliki Bistola, Filippos Triposkiadis, Ignatios Ikonomidis, Spyridon Katsanos, George Bakosis, Erifili Hatziagelaki, John Lekakis, Alexandre Mebazaa, John Parissis
BACKGROUND: Heart failure with mid-range left ventricular ejection fraction (HFmrEF) is a poorly characterized population as it has been studied either in the context of HF with reduced (HFrEF) or preserved (HFpEF) left ventricular ejection fraction (LVEF) depending on applied LVEF cutoffs. We sought to investigate the clinical profile, in-hospital management, and short-term outcome of HFmrEF patients in comparison with those with HFrEF or HFpEF in a large acute HF cohort. METHODS AND RESULTS: The Acute Heart Failure Global Registry of Standard Treatment (ALARM-HF) included 4953 patients hospitalized for HF in nine countries in Europe, Latin America, and Australia...
December 20, 2016: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/27999359/diabetic-cardiomyopathy-does-the-type-of-diabetes-matter
#19
REVIEW
Maximilian E Hölscher, Christoph Bode, Heiko Bugger
In recent years, type 2 diabetes mellitus has evolved as a rapidly increasing epidemic that parallels the increased prevalence of obesity and which markedly increases the risk of cardiovascular disease across the globe. While ischemic heart disease represents the major cause of death in diabetic subjects, diabetic cardiomyopathy (DC) summarizes adverse effects of diabetes mellitus on the heart that are independent of coronary artery disease (CAD) and hypertension. DC increases the risk of heart failure (HF) and may lead to both heart failure with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF)...
December 18, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27995390/the-three-decade-long-journey-in-heart-failure-drug-development
#20
Kelly S Lewis, Javed Butler, Johann Bauersachs, Peter Sandner
Heart failure is a global disease with increasing prevalence due to an aging worldwide population with increasing co-morbidities. Despite several therapeutic options available to treat HFrEF, morbidity and mortality remain high. Importantly, no approved therapies are available to treat HFpEF. This paper will briefly summarize the burden of disease, HF classification and definitions and the landmark clinical trials in both HFrEF and HFpEF. Given the increasing incidence and prevalence of HF and the high morbidity and mortality associated with this disease, continued development efforts are essential to address the unmet needs of these patients...
December 20, 2016: Handbook of Experimental Pharmacology
keyword
keyword
71067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"